Development of Organ-specific Treatment for Bone Metastasis in Neuroblastoma
| Project/Area Number |
14570793
|
|---|
| Research Category |
Grant-in-Aid for Scientific Research (C)
|
| Allocation Type | Single-year Grants |
|---|
| Section | 一般 |
|---|
| Research Field |
Pediatrics
|
|---|
| Research Institution | Osaka Medical Center and Research Institute for Maternal and Child Health |
|---|
Principal Investigator |
MICHIGAMI Toshimi Osaka Medical Center and Research Institute for Maternal and Child Health, Department of Environmental Medicine, Chief, 環境影響部門, 部長 (00301804)
|
|---|
| Co-Investigator(Kenkyū-buntansha) |
OZONO Keiichi Osaka University Graduate School Medicine, Department of Pediatrics, Professor, 大学院・医学研究科・生体統合医学・小児発達医学, 教授 (20270770)
|
|---|
| Project Period (FY) |
2002 – 2003
|
| Project Status |
Completed (Fiscal Year 2003)
|
| Budget Amount *help |
¥2,900,000 (Direct Cost: ¥2,900,000)
Fiscal Year 2003: ¥800,000 (Direct Cost: ¥800,000)
Fiscal Year 2002: ¥2,100,000 (Direct Cost: ¥2,100,000)
|
|---|
| Keywords | neuroblastoma / bone metastasis / RANKL / gene therapy / osteoprotegerin / 破骨細胞 / 筋肉内遺伝子導入 |
|---|
| Research Abstract |
Bone metastasis in neuroblastoma is an unfavorable prognostic factor even with intensive therapy. We have previously reported that nuclear factor κB ligand (RANKL) expression is stimulated in the coculture of human neuroblastoma cell line and murine bone marrow cells containing osteoclast precursors and stromal cells, compared with the culture of bone marrow cells alone. As the result, osteoclastogenesis was increased in the coculture. In other cancers such as prostate cancer and multiple myeloma as well, RANKL signaling is suggested to play a role. In an attempt to develop an organ-specific treatment for bone metastasis in neuroblastoma, we examined the effect of gene therapy using osteoprotegerin (OPG) expression vector in some animal models of osteolytic bone diseases. As the expression vector, we utilized pCAGGS containing CAG promoter. We constructed pCAGGS-OPG-FLAG, and confirmed the biological activity of OPG-FLAG in an in vitro osteoclastogenesis assay. To introduce pCAGGS-OPG-FLAG into the muscle of animals, we utilized naked DNA injection method combined with electroporation. In animal models of humoral hypercalcemia of malignancy, introduction of pCAGGS-OPG-FLAG restored hypercalcemia. In OPG knockout mice, the treatment using pCAGGS-OPG-FLAG increased bone mineral density. These data suggested the usefulness of treatment targeting RANKL signaling in osteolytic bone diseases, containing bone metasatsis in neuroblastoma.
|
Report
(3 results)
Research Products
(8 results)
